Sharyn Ruperti first started working with Novocure about 10 years ago as one of six Device Support Specialists supporting patients on the company’s first pivotal trial. She’s had the opportunity to witness the company’s progress firsthand.

“Novocure has grown significantly in the past several years. We are now a global company with more than 450 employees, two FDA approvals and a robust clinical pipeline,” Sharyn said. “It’s an exciting time to be a part of Novocure.”

By 2012, Sharyn had obtained her master’s degree in clinical research administration and joined the Clinical Operations Team as an Assistant Clinical Trial Manager. Now a Clinical Trial Manager, Sharyn performs a variety of functions.

“I am responsible for the day-to-day management of the company’s METIS trial in brain metastases from non-small cell lung cancer. I provide oversight of our clinical research organization and work to ensure study metrics are met,” Sharyn said. “I also visit doctors at participating trial sites and train them on the science of alternating electric field therapy and how to explain the therapy to potential study participants.”

I feel like I am truly making a difference for patients and their families.”

During her time at Novocure, Sharyn said, the patient-forward culture has remained consistent. It is this mentality that she noted doctors cite as something that sets the company apart.

“We go out of our way to help patients. I know that every patient matters,” Sharyn said. “Patients on our therapy are not viewed only as a ‘subject’ or study ID number – they are people with loved ones, and the company works hard to help each individual patient.”

Sharyn ultimately feels motivated by the patient-centric approach.

“I feel like I am truly making a difference for patients and their families,” she said.

Treatment with TTFields is not approved for the treatment of brain metastases from non-small cell lung cancer by the U.S. Food and Drug Administration. The safety and effectiveness of TTFields therapy for brain metastases from non-small cell lung cancer has not been established.